Background and Objective: Recent studies have revealed that circulating ghrelin levels seem to play a role in energy homeostasis. The effect of hyperthyroidism on ghrelin levels is not fully known. Methods: Serum levels of ghrelin and its relationship with insulin resistance were evaluated in 48 patients with hyperthyroidism and 43 euthyroid healthy controls. Thyroid hormones, insulin, glucose, ghrelin levels and lipid parameters were measured in all subjects. Insulin sensitivity was determined using the homeostasis model assessment. Results: Serum ghrelin levels were significantly decreased in hyperthyroid patients than in controls (32.5 ± 23.3 vs. 54.1 ± 35.5 pg/ml, p < 0.001). Circulating ghrelin levels significantly correlated with age (r = –0.26, p = 0.01), fasting glucose (r = –0.21, p = 0.01), free triiodothyronine (r = –0.18, p = 0.04), free thyroxine (r = –0.23, p = 0.02) and thyroid stimulating hormone (r = 0.21, p = 0.04), but not with blood pressure, body mass index, lipid parameters, insulin and homeostasis model assessment (p > 0.05). Multiple regression analysis revealed glucose level to be the most important predictor of circulating ghrelin level. Conclusion: These results indicate that hyperthyroidism has effect on serum ghrelin levels. Further studies are needed for the exact mechanism.

1.
Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K: Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 1999;402:656–660.
2.
Takaya K, Ariyasu H, Kanamoto N, Iwakura H, Yoshimoto A, Harada M, Mori K, Komatsu Y, Usui T, Shimatsu A, Ogawa Y, Hosoda K, Akamizu T, Kojima M, Kangawa K, Nakao K: Ghrelin strongly stimulates growth hormone release in humans. J Clin Endocrinol Metab 2000;85:4908–4911.
3.
Gnanapavan S, Kola B, Bustin SA, Morris DG, McGee P, Fairclough P, Bhattacharya S, Carpenter R, Grossman AB, Korbonits M: The tissue distribution of the mRNA of ghrelin and subtypes of its receptor, GHS-R, in humans. J Clin Endocrinol Metab 2002;87:2988.
4.
Tschop M, Smiley DL, Heiman ML: Ghrelin induces adiposity in rodents. Nature 2000;407:908–913.
5.
Wren AM, Small CJ, Ward HL, Murphy KG, Dakin CL, Taheri S, Kennedy AR, Roberts GH, Morgan DG, Ghatei MA, Bloom SR: The novel hypothalamic peptide ghrelin stimulates food intake and growth hormone secretion. Endocrinology 2000;141:4325–4328.
6.
Wren AM, Seal LJ, Cohen MA, Brynes AE, Frost GS, Murphy KG, Dhillo WS, Ghatei MA, Bloom SR: Ghrelin enhances appetite and increases food intake in humans. J Clin Endocrinol Metab 2001;86:5992.
7.
Wren AM, Small CJ, Abbott CR, Dhillo WS, Seal LJ, Cohen MA, Batterham RL, Taheri S, Stanley SA, Ghatei MA, Bloom SR: Ghrelin causes hyperphagia and obesity in rats. Diabetes 2001;50:2540–2547.
8.
Cummings DE, Purnell JQ, Frayo RS, Schmidova K, Wisse BE, Weigle DS: A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes 2001;50:1714–1719.
9.
Cummings DE, Frayo RS, Marmonier C, Aubert R, Chapelot D: Plasma ghrelin levels and hunger scores in humans initiating meals voluntarily without time- and food-related cues. Am J Physiol Endocrinol Metab 2004;287:297–304.
10.
Jarkovska Z, Krsek M, Rosicka M, Marek J: Endocrine and metabolic activities of a recently isolated peptide hormone ghrelin, an endogenous ligand of the growth hormone secretagogue receptor. Endocr Regul 2004;38:80–86.
11.
Hansen TK, Dall R, Hosoda H, Kojima M, Kangawa K, Christiansen JS, Jorgensen JO: Weight loss increases circulating levels of ghrelin in human obesity. Clin Endocrinol (Oxf) 2002;56:203–206.
12.
Tschop M, Weyer C, Tataranni PA, Devanarayan V, Ravussin E, Heiman ML: Circulating ghrelin levels are decreased in human obesity. Diabetes 2001;50:707–709.
13.
Cummings DE, Weigle DS, Frayo RS, Breen PA, Ma MK, Dellinger EP, Purnell JQ: Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Engl J Med 2002;346:1623–1630.
14.
Nagaya N, Uematsu M, Kojima M, Date Y, Nakazato M, Okumura H, Hosoda H, Shimizu W, Yamagishi M, Oya H, Koh H, Yutani C, Kangawa K: Elevated circulating level of ghrelin in cachexia associated with chronic heart failure: relationships between ghrelin and anabolic/catabolic factors. Circulation 2001;104:2034–2038.
15.
Otto B, Cuntz U, Fruehauf E, Wawarta R, Folwaczny C, Riepl RL, Heiman ML, Lehnert P, Fichter M, Tschop M: Weight gain decreases elevated plasma ghrelin concentrations of patients with anorexia nervosa. Eur J Endocrinol 2001;145:669–673.
16.
Flanagan DE, Evans ML, Monsod TP, Rife F, Heptulla RA, Tamborlane WV, Sherwin RS: The influence of insulin on circulating ghrelin. Am J Physiol Endocrinol Metab 2003;284:313–316.
17.
Saad MF, Bernaba B, Hwu CM, Jinagouda S, Fahmi S, Kogosov E, Boyadjian R: Insulin regulates plasma ghrelin concentration. J Clin Endocrinol Metab 2002;87:3997–4000.
18.
Mohlig M, Spranger J, Otto B, Ristow M, Tschop M, Pfeiffer AF: Euglycemic hyperinsulinemia, but not lipid infusion, decreases circulating ghrelin levels in humans. J Endocrinol Invest 2002;25:36–38.
19.
Caixas A, Bashore C, Nash W, Pi-Sunyer F, Laferrere B: Insulin, unlike food intake, does not suppress ghrelin in human subjects. J Clin Endocrinol Metab 2002;87:1902.
20.
Schaller G, Schmidt A, Pleiner J, Woloszczuk W, Wolzt M, Luger A: Plasma ghrelin concentrations are not regulated by glucose or insulin: a double-blind, placebo-controlled crossover clamp study. Diabetes 2003;52:16–20.
21.
Bech K, Damsbo P, Eldrup E, Beck-Nielsen H, Roder ME, Hartling SG, Volund A, Madsbad S: Beta-cell function and glucose and lipid oxidation in Graves’ disease. Clin Endocrinol (Oxf) 1996;44:59–66.
22.
Tene C, Zarate A, Basurto L, Islas S, Revilla C, Ochoa R, Galvan R, Santos P: Correction of insulin resistance in methimazole-treated patients with Graves disease. Rev Invest Clin 2001;53:531–535.
23.
Caminos JE, Seoane LM, Tovar SA, Casanueva FF, Dieguez C: Influence of thyroid status and growth hormone deficiency on ghrelin. Eur J Endocrinol 2002;147:159–163.
24.
Gimenez-Palop O, Gimenez-Perez G, Mauricio D, Berlanga E, Potau N, Vilardell C, Arroyo J, Gonzalez-Clemente JM, Caixas A: Circulating ghrelin in thyroid dysfunction is related to insulin resistance and not to hunger, food intake or anthropometric changes. Eur J Endocrinol 2005;153:73–79.
25.
Riis AL, Hansen TK, Moller N, Weeke J, Jorgensen JO: Hyperthyroidism is associated with suppressed circulating ghrelin levels. J Clin Endocrinol Metab 2003;88:853–857.
26.
Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499–502.
27.
Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412–419.
28.
Jap TS, Ho LT, Won JG: Insulin secretion and sensitivity in hyperthyroidism. Horm Metab Res 1989;21:261–266.
29.
Zahorska-Markiewicz B, Mizia-Stec K, Olszanecka-Glinianowicz M, Janowska J: Effect of weight reduction on serum ghrelin and TNFalpha concentrations in obese women. Eur J Intern Med 2004;15:172–175.
30.
Holdstock C, Ludvigsson J, Karlsson FA: Abnormal ghrelin secretion in new onset childhood Type 1 diabetes. Diabetologia 2004;47:150–151.
31.
Choi KM, Lee J, Lee KW, Seo JA, Oh JH, Kim SG, Kim NH, Choi DS, Baik SH: The associations between plasma adiponectin, ghrelin levels and cardiovascular risk factors. Eur J Endocrinol 2004;150:715–718.
32.
Fagerberg B, Hulten LM, Hulthe J: Plasma ghrelin, body fat, insulin resistance, and smoking in clinically healthy men: the atherosclerosis and insulin resistance study. Metabolism 2003;52:1460–1463.
33.
Rojdmark S, Calissendorff J, Danielsson O, Brismar K: Hunger-satiety signals in patients with graves’ thyrotoxicosis before, during, and after long-term pharmacological treatment. Endocrine 2005;27:55–62.
34.
Nakagawa E, Nagaya N, Okumura H, Enomoto M, Oya H, Ono F, Hosoda H, Kojima M, Kangawa K: Hyperglycaemia suppresses the secretion of ghrelin, a novel growth-hormone-releasing peptide: responses to the intravenous and oral administration of glucose. Clin Sci (Lond) 2002;103:325–328.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.